"Lupus Nephritis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Descriptor ID |
D008181
|
MeSH Number(s) |
C12.777.419.570.363.680 C13.351.968.419.570.363.680 C17.300.480.680 C20.111.590.560
|
Concept/Terms |
Lupus Nephritis- Lupus Nephritis
- Lupus Glomerulonephritis
- Nephritis, Lupus
- Lupus Nephritides
- Nephritides, Lupus
- Glomerulonephritis, Lupus
- Glomerulonephritides, Lupus
- Lupus Glomerulonephritides
|
Below are MeSH descriptors whose meaning is more general than "Lupus Nephritis".
Below are MeSH descriptors whose meaning is more specific than "Lupus Nephritis".
This graph shows the total number of publications written about "Lupus Nephritis" by people in this website by year, and whether "Lupus Nephritis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1999 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 2 | 0 | 2 |
2005 | 4 | 0 | 4 |
2006 | 1 | 0 | 1 |
2007 | 2 | 1 | 3 |
2008 | 3 | 0 | 3 |
2009 | 5 | 4 | 9 |
2011 | 2 | 1 | 3 |
2012 | 2 | 3 | 5 |
2013 | 4 | 0 | 4 |
2014 | 4 | 0 | 4 |
2015 | 6 | 1 | 7 |
2016 | 4 | 0 | 4 |
2017 | 1 | 1 | 2 |
2019 | 2 | 1 | 3 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
2022 | 3 | 0 | 3 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lupus Nephritis" by people in Profiles.
-
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther. 2024 02 20; 26(1):54.
-
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
-
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024 Jan 23; 9(2).
-
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford). 2022 11 02; 61(11):4335-4343.
-
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
-
Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. Arthritis Rheumatol. 2022 05; 74(5):829-839.
-
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Sci Med. 2021 08; 8(1).
-
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 05 29; 397(10289):2070-2080.
-
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020 02; 72(2):233-242.
-
Lupus Nephritis: Duration of Therapy and Possibility of Withdrawal. Adv Chronic Kidney Dis. 2019 09; 26(5):387-392.